TrialDiabetes, obesity & metabolism2020

Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial.

Mark E Cooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.